The STUDIA UNIVERSITATIS BABEŞ-BOLYAI issue article summary

The summary of the selected article appears at the bottom of the page. In order to get back to the contents of the issue this article belongs to you have to access the link from the title. In order to see all the articles of the archive which have as author/co-author one of the authors mentioned below, you have to access the link from the author's name.

 
       
         
    STUDIA BIOETHICA - Issue no. 2 / 2011  
         
  Article:   THE PRECAUTIONARY PRINCIPLE: HISTORICAL AND CONCEPTUAL BACKGROUND.

Authors:  BARBARA OSIMANI.
 
       
         
  Abstract:  Pharmaceutical decisions are affected by several forms of uncertainty which are sharpened both by the high stakes at play, and by the complexity of the epistemological procedures needed to provide the necessary information. The precautionary principle as applied to pharmaceutical decisions through the notion of “well-founded suspicion” takes into account one special sort of these uncertainties: the uncertainty concerning the causal connection between observed adverse reactions and suspected drug. The introduction of the precautionary principle has meant the shift from a legal system based on danger avoidance – where causality must be certain before any countermeasure is allowed/enforced – to a risk prevention system, where the hypothesis of causal connection may be as weakly supported by evidence as the expected harm is high. In this sense, the notion of well founded suspicion is equivalent to that of “hypothesis of causal connection” and it is measured probabilistically. Thus we have in principle two probabilities: one attached to the hypothesis that there is indeed a causal connection between expected harm and drug; the other measuring the expectation that the harm indeed occurs (possibly as a function of its incidence in the “population”). The higher the former, the more confident are we about the harm-drug connection, the higher the latter, the higher is the expected harm.

Keywords: precautionary principle, risk analysis, risk aversion, causality, pharmaceutical regulation
 
         
     
         
         
      Back to previous page